Get the Stockscreener App
6.37
14.16%
0.79
After Hours:
6.30
-0.07
-1.10%
Evolus Inc stock is traded at $6.37, with a volume of 3.92M.
It is up +14.16% in the last 24 hours and up +58.06% over the past month.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
See More
Previous Close:
$5.58
Open:
$5.45
24h Volume:
3.92M
Relative Volume:
3.55
Market Cap:
$419.49M
Revenue:
$297.18M
Net Income/Loss:
$-51.64M
P/E Ratio:
-7.9298
EPS:
-0.8033
Net Cash Flow:
$-50.72M
1W Performance:
+20.87%
1M Performance:
+58.06%
6M Performance:
-6.46%
1Y Performance:
-46.96%
1-Day Range:
$5.45
$6.665
1-Week Range:
$5.115
$6.665
52-Week Range:
$3.86
$12.15
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.37 | 367.47M | 297.18M | -51.64M | -50.72M | -0.8033 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus, Inc. (NASDAQ:EOLS) Q1 2026 Earnings Call Transcript - Insider Monkey
Evolus, Inc. 2026 Q1 Financial Report: Key Risks, Financials, and Business Updates - Minichart
Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin - MSN
Earnings call transcript: Evolus misses Q1 2026 EPS forecast, revenue up - Investing.com UK
Evolus Q1 2026 earnings preview - MSN
Evolus, Inc. (EOLS) reports Q1 loss, tops revenue estimates - MSN
Evolus Earnings Call Highlights Profitable Growth Path - TipRanks
Evolus, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance Singapore
Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally - ChartMill
Evolus Q1 Earnings Call Highlights - Yahoo Finance
Evolus Posts Mixed Q1 Results - Orange County Business Journal
Evolus (EOLS) Q1 2026 Earnings Transcript - AOL.com
EOLS Reports Strong Q1 Revenue and Positive Adjusted EBITDA - GuruFocus
Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary - TradingView
Evolus (NASDAQ: EOLS) grows Q1 2026 sales but remains unprofitable - Stock Titan
Evolus Ends ATM Facility After Strong Q1 Momentum - TipRanks
Evolus Inc. (EOLS) stock falls on Q1 2026 Earnings - Quiver Quantitative
Evolus (NASDAQ: EOLS) Q1 2026 earnings, guidance and growth outlook - Stock Titan
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook - Business Wire
Weight-loss revolution sparks new appetite for aesthetics firms - marketscreener.com
Trading the Move, Not the Narrative: (EOLS) Edition - Stock Traders Daily
Evolus (NASDAQ: EOLS) plans 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
[ARS] Evolus, Inc. SEC Filing - Stock Titan
Evolus Deadline Alert - TMX Newsfile
Evolus Q1 2025 Earnings Preview - MSN
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions - Yahoo Finance
EVOLUS DEADLINE ALERT - TMX Newsfile
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Short Interest in Evolus, Inc. (NASDAQ:EOLS) Drops By 14.4% - MarketBeat
Evolus, Inc. (EOLS) Stock Analysis: Unpacking A 223% Potential Upside - DirectorsTalk Interviews
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript - MSN
Evolus to Report First Quarter Financial Results on May 4, 2026 - Barchart
Aug Big Picture: What analysts say about Evolus Inc stockQuarterly Investment Review & AI Based Trade Execution Alerts - baoquankhu1.vn
Bank Watch: What is the earnings history of Evolus Inc2026 Reactions & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
How safe is Evolus (EOLS) Stock dividend | Price at $4.25, Down 0.59%Social Trade Signals - Xã Vĩnh Công
Evolus and Oramed Pharmaceuticals Compared - National Today
How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts - Yahoo Finance
Evolus (LTS:0K16) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Street Watch: Is Evolus Inc showing insider buying2026 PostEarnings & Real-Time Buy Signal Notifications - baoquankhu1.vn
EOLS Stock Price, Quote & Chart | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Is Evolus (EOLS) Stock trading above fair value | Price at $4.12, Up 0.61%Expert Insights - Cổng thông tin điện tử Tỉnh Sơn La
Tech Rally: Is Evolus Inc undervalued by DCF analysisQuarterly Earnings Report & Verified Swing Trading Watchlists - baoquankhu1.vn
Winners Losers: Is Evolus Inc showing insider buying2026 EndofMonth & Breakout Confirmation Trade Signals - baoquankhu1.vn
EOLS Stock Analysis: Evolus Inc. Drops 6.5 Pct to 4.03 USD Near Term Support In Focus - Cổng thông tin điện tử tỉnh Tây Ninh
FY2026 Earnings Forecast for Evolus Issued By HC Wainwright - MarketBeat
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference - BioSpace
Market Leaders: What analysts say about Evolus Inc stockWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):